Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum
Use
This test is useful for investigating idiopathic dysautonomic symptoms and directing a focused search for cancer in patients with idiopathic dysautonomia. It helps differentiate autoimmune dysautonomia from the effects of chemotherapy by detecting autoantibodies, which may indicate autonomic symptoms appearing during or after cancer therapy not explained by recurrent cancer or metastasis.
Special Instructions
Not provided.
Limitations
Negative results do not exclude autoimmune dysautonomia or cancer. Intravenous immunoglobulin (IVIg) treatment prior to serum collection may cause a false-positive result.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 99000-2 - Dysauto autoimmune Ab pnl Ser
- 33615-6 - Hu1 Ab Ser Ql
- 72504-4 - CV2 Ab SerPl Ql IF
- 94694-7 - nAChR Ab Ser IA-sCnc
- 84925-7 - PCA-2 Ab Ser Ql IF
- 69048-7 - Immunologist review
- 48767-8 - Annotation comment Imp
- 94287-0 - LGI1 IgG Ser Ql CBA IFA
- 94285-4 - CASPR2 IgG Ser Ql CBA IFA
- 94676-4 - DPPX IgG Ser Ql CBA IFA
- 101907-4 - AP3B2 IgG Spec Ql
Result Turnaround Time
8-12 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
4 mL
Minimum Volume
2.5 mL
Container
Red top (preferred); Serum gel (acceptable). Submission container: Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
For optimal antibody detection, specimen collection is recommended before starting immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |